Q3 Earnings: Surveying The Small Biopharma Launch Scene
Executive Summary
Several small biopharmas are launching new drugs independently, sales of some of those drugs appear to be off to a slow start.
You may also be interested in...
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
New Gene Therapies Have Hit The Market; Drug Makers Discuss Initial Launch Trends
BioMarin, Sarepta and bluebird bio are all launching new gene therapies in the US. The drug makers updated investors on the commercial execution during second quarter financial earnings calls.
Astellas’ Izervay Joins Geographic Atrophy Market, Intensifying Competition
The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.